Table 1.
Expression of PD-L1 and genetic alteration in each oncogenic pathway in HCC
| Oncogenic pathwaya | PD-Ll-positive HCC (n = 40) | PD-Ll-negative HCC (n = 114) | p valueb |
|---|---|---|---|
| β-catenin | |||
| Alteration (+) | 5 | 34 | 0.0302 |
| Alteration (−) | 35 | 80 | |
| p53/cell cycle control | |||
| Alteration (+) | 15 | 37 | 0.5617 |
| Alteration (−) | 25 | 77 | |
| Chromatin remodeling | |||
| Alteration (+) | 7 | 17 | 0.6979 |
| Alteration (−) | 33 | 97 | |
| Epigenetic regulator | |||
| Alteration (+) | 5 | 19 | 0.5319 |
| Alteration (−) | 35 | 95 | |
| PI3K-Akt | |||
| Alteration (+) | 8 | 8 | 0.0206 |
| Alteration (−) | 32 | 106 | |
| Oxidative and ER stress | |||
| Alteration (+) | 3 | 12 | 0.5786 |
| Alteration (−) | 37 | 102 | |
| DNA repair | |||
| Alteration (+) | 3 | 11 | 0.6842 |
| Alteration (−) | 37 | 103 | |
| TERT promoter | |||
| Alteration (+) | 26 | 73 | 0.9127 |
| Alteration (−) | 14 | 41 | |
Bold type denotes significance.
a
The presence or absence of alteration in the oncogenic pathway was determined based on the mutations, homozygous deletion, and/or amplification of cancer-related genes in each pathway.
b
Pearson's χ2 test.